<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1474">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01740817</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20080015H</org_study_id>
    <secondary_id>5R01DK080157</secondary_id>
    <nct_id>NCT01740817</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Lipid Infusion on Toll Like Receptor 4 (TLR4) Signaling</brief_title>
  <official_title>A Randomized, Crossover Study to Evaluate the Effect of Lipid Infusion on TLR4 Signaling and Insulin Resistance in Human Muscle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a lipid infusion can up-regulate toll-like
      receptor 4 (TLR4) signaling in human subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators plan to examine the effect of a lipid infusion on TLR4 expression and
      insulin sensitivity. A group of 30 subjects aged 18-60 years old, lean (BMI &lt; 26 kg/m2)
      normal glucose tolerant subjects without a family history of type 2 diabetes will receive a
      lipid or saline infusion. The subjects will be randomly assigned to first receive either a
      48 hour long lipid or saline infusion. Approximately 4-6 weeks later subjects will return to
      undergo another study (if, in the first study they received lipid, on the second study they
      will receive saline, and vice versa). A near-equal number of women and men will be included
      in each group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Muscle Insulin Sensitivity-M Value</measure>
    <time_frame>48 hr after lipid/saline infusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Forty eight hrs after lipid or saline infusion, muscle insulin sensitivity will be measured by insulin clamp. The results are compared to determine whether lipid infusion reduces muscle insulin sensitivity compared to saline infusion..
The M value is defined as the exogenous glucose infusion rate at steady state (i.e, when the exogenous glucose infusion rate is equal to the rate of whole body glucose disposal).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TLR4 Messenger Ribonucleic Acid (mRNA) in Muscle</measure>
    <time_frame>48 hr following lipid/saline infusion, pre-clamp</time_frame>
    <safety_issue>No</safety_issue>
    <description>Forty eight hrs after lipid or saline infusion, muscle TLR4 mRNA levels will be measured by RT-PCR. The results are compared to determine whether lipid infusion increases muscle TLR4 mRNA expression compared to saline infusion.
Saline mean was used to normalize the data for both arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracellular Signal-regulated Kinase (ERK) Phosphorylation in Muscle</measure>
    <time_frame>48 hr following lipid or saline infusion, pre-clamp</time_frame>
    <safety_issue>No</safety_issue>
    <description>Forty eight hrs after lipid or saline infusion, muscle ERK phosphorylation will be measured by western blot. The results are compared to determine whether lipid infusion increases muscle ERK phosphorylation compared to saline infusion. Saline mean was used to normalize the data for both arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Intralipid 20%, then saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first received lipid infusion of 30ml/h x48h. After a washout period of 4-6 weeks, they then received saline infusion of 30ml/h x48h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline, then Intralipid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first received saline infusion of 30ml/h x48h. After a washout period of 4-6 weeks, they then received lipid infusion of 30ml/h x48h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid 20%</intervention_name>
    <description>30 ml/h for 48 h</description>
    <arm_group_label>Intralipid 20%, then saline</arm_group_label>
    <arm_group_label>Saline, then Intralipid</arm_group_label>
    <other_name>Liposyn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>30 ml/h for 48 h</description>
    <arm_group_label>Intralipid 20%, then saline</arm_group_label>
    <arm_group_label>Saline, then Intralipid</arm_group_label>
    <other_name>sodium chloride injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must have the following laboratory values: Hematocrit ≥ 35%, serum
             creatinine ≤ 1.5 mg/dl, aspartate aminotransferase (AST) &lt; 2 X upper limit of normal,
             Alanine aminotransferase (ALT) &lt; 2 X upper limit of normal, alkaline phosphatase &lt; 2
             X upper limit of normal, normal urinalysis [no glucose, trace protein, trace ketones,
             lipase &lt; 50 IU/L, no bacteria, up to 1-3 white blood cells (WBC) and red blood cells
             (RBC) per hpf], and normal platelets, prothrombin time (PT) and partial
             thromboplastin time (PTT).

          2. Female subjects must be non-lactating. Female patients are eligible only if they have
             a negative pregnancy test throughout the study period (or postmenopausal).
             Postmenopausal women taking hormone replacement will be included if they have been on
             a stable dose for ≥6 months.

          3. Subjects whose body weight has been stable (within 2%) for at least three months.

        Exclusion Criteria:

          1. Subjects with impaired glucose tolerance based on American Diabetes Association
             criteria.

          2. Subjects taking drugs known to affect glucose and lipid homeostasis will be excluded.
             Statins will be permitted if the subject has been on a stable dose for at least three
             months. Subjects who have taken for more than a week non-steroidal anti inflammatory
             drugs (NSAIDS) within two months or systemic steroids, anabolic steroids, growth
             hormone or immunosuppressants within 12 months will be excluded. Subjects taking
             low-dose (81 mg/day or less) aspirin will be allowed.

          3. Patients with a history of clinically significant heart disease (New York Heart
             Classification greater than grade II; more than non-specific ST-T wave changes on the
             EKG), peripheral vascular disease (history of claudication), or pulmonary disease
             (dyspnea on exertion of one flight or less; abnormal breath sounds on auscultation)
             will not be studied.

          4. Recent systemic or pulmonary embolus, impaired renal function, poorly controlled
             blood pressure (systolic BP&gt;170, diastolic BP&gt;95), resting heart rate &gt;100,
             electrolyte abnormalities, neuromuscular or musculoskeletal disease.

          5. Subjects who smoke.

          6. Subjects who engage in a regular exercise program (zero or one exercise sessions per
             week are allowed).

          7. Any subject who has donated blood in the previous two months.

          8. Any subject with a hematocrit of less than 35.

          9. Subjects who are claustrophobic.

         10. Women taking oral contraceptives.

         11. alcohol consumption greater than 30 grams daily.

         12. baseline plasma triglyceride levels over 200 mg/dl
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Musi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univerisity of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Audie L. Murphy VA Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 18, 2015</lastchanged_date>
  <firstreceived_date>November 26, 2012</firstreceived_date>
  <firstreceived_results_date>June 30, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Nicolas Musi, MD</investigator_full_name>
    <investigator_title>Professor Diabetes Division</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>obesity</keyword>
  <keyword>inflammation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>12 of 52 participants were randomized. Of those not randomized, 40 did not meet inclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lipid Then Saline</title>
          <description>Intralipid 20% 30 ml/h for 48 h, then saline 30 ml/h for 48 h</description>
        </group>
        <group group_id="P2">
          <title>Saline Then Lipid</title>
          <description>Saline infusion 30 ml/h for 48 h, then lipid 30 ml/h for 48 h</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (48 h)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (4-6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (48 h)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Participants who were randomized to receive either lipid or saline</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="39" spread="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Muscle Insulin Sensitivity-M Value</title>
        <description>Forty eight hrs after lipid or saline infusion, muscle insulin sensitivity will be measured by insulin clamp. The results are compared to determine whether lipid infusion reduces muscle insulin sensitivity compared to saline infusion..
The M value is defined as the exogenous glucose infusion rate at steady state (i.e, when the exogenous glucose infusion rate is equal to the rate of whole body glucose disposal).</description>
        <time_frame>48 hr after lipid/saline infusion</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Saline</title>
            <description>Saline infusion at 30 ml/h for 48 h</description>
          </group>
          <group group_id="O2">
            <title>Intralipid</title>
            <description>liposyn infusion at 30 ml/h for 48 hrs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Muscle Insulin Sensitivity-M Value</title>
            <description>Forty eight hrs after lipid or saline infusion, muscle insulin sensitivity will be measured by insulin clamp. The results are compared to determine whether lipid infusion reduces muscle insulin sensitivity compared to saline infusion..
The M value is defined as the exogenous glucose infusion rate at steady state (i.e, when the exogenous glucose infusion rate is equal to the rate of whole body glucose disposal).</description>
            <units>mg/kg.min</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9.9" spread="0.7"/>
                  <measurement group_id="O2" value="8.3" spread="0.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TLR4 Messenger Ribonucleic Acid (mRNA) in Muscle</title>
        <description>Forty eight hrs after lipid or saline infusion, muscle TLR4 mRNA levels will be measured by RT-PCR. The results are compared to determine whether lipid infusion increases muscle TLR4 mRNA expression compared to saline infusion.
Saline mean was used to normalize the data for both arms.</description>
        <time_frame>48 hr following lipid/saline infusion, pre-clamp</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Saline</title>
            <description>Saline infusion at 30 ml/h for 48 h</description>
          </group>
          <group group_id="O2">
            <title>Intralipid</title>
            <description>liposyn infusion at 30 ml/h for 48 hrs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>TLR4 Messenger Ribonucleic Acid (mRNA) in Muscle</title>
            <description>Forty eight hrs after lipid or saline infusion, muscle TLR4 mRNA levels will be measured by RT-PCR. The results are compared to determine whether lipid infusion increases muscle TLR4 mRNA expression compared to saline infusion.
Saline mean was used to normalize the data for both arms.</description>
            <units>ng TLR4 mRNA/ng Actin mRNA</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1" spread="0.15"/>
                  <measurement group_id="O2" value="1.6" spread="0.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extracellular Signal-regulated Kinase (ERK) Phosphorylation in Muscle</title>
        <description>Forty eight hrs after lipid or saline infusion, muscle ERK phosphorylation will be measured by western blot. The results are compared to determine whether lipid infusion increases muscle ERK phosphorylation compared to saline infusion. Saline mean was used to normalize the data for both arms.</description>
        <time_frame>48 hr following lipid or saline infusion, pre-clamp</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Saline</title>
            <description>Saline infusion at 30 ml/h for 48 h</description>
          </group>
          <group group_id="O2">
            <title>Intralipid</title>
            <description>liposyn infusion at 30 ml/h for 48 hrs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Extracellular Signal-regulated Kinase (ERK) Phosphorylation in Muscle</title>
            <description>Forty eight hrs after lipid or saline infusion, muscle ERK phosphorylation will be measured by western blot. The results are compared to determine whether lipid infusion increases muscle ERK phosphorylation compared to saline infusion. Saline mean was used to normalize the data for both arms.</description>
            <units>densitometry value</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" spread="0.18"/>
                  <measurement group_id="O2" value="1.95" spread="0.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Saline</title>
          <description>Intralipid infusion 20%, at 30 ml/h for 48 h, then washout 4-6 weeks, then saline 30 ml/h for 48 h</description>
        </group>
        <group group_id="E2">
          <title>Intralipid</title>
          <description>Saline infusion 20%, at 30 ml/h for 48 h, then washout 4-6 weeks, then Intralipid 30 ml/h for 48 h</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nicolas Musi</name_or_title>
      <organization>University of Texas Health Science Center at San Antonio</organization>
      <phone>200-562-6152</phone>
      <email>musi@uthscsa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
